30 April - 3 May 2022 in ADELAIDE, SOUTH AUSTRALIA

Abstract Number: 21

Tildrakizumab for the treatment of probable pyoderma gangrenosum with periosteal involvement

Abstract Number: 22

The effect of weight and body mass index (BMI) on choice of biologic therapy and drug survival in patients with psoriasis

Abstract Number: 23

Taltz (Ixekizumab) for management of necrobiosis lipoidica diabeticorum: a case presentation

Abstract Number: 24

Tuberculosis testing for patients commencing Dupixent (dupilumab): our experience and recommendations

Abstract Number: 25

Expectation versus reality: Results of an audit of real-world outcomes of Dupixent (dupilumab) when assessed by quality of life and clinical measures in an outpatient clinic population

Abstract Number: 26

Certolizumab pegol for treatment of plaque psoriasis: pooled efficacy outcomes across baseline Psoriasis Area and Severity Index subgroups (CIMPASI-1 and CIMPASI-2)

Abstract Number: 27

Rituximab for the treatment of pemphigus vulgaris in Australia: A cost-utility analysis

Abstract Number: 28

Bimekizumab efficacy and safety up to two years in patients with moderate to severe plaque psoriasis switching from ustekinumab: Results from the interim BE BRIGHT open-label extension trial

Abstract Number: 29

Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

Abstract Number: 30

Safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis: Long-term results from BE SURE randomised controlled trial and BE BRIGHT open-label extension